CR Group L.P. - 14 Feb 2024 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)

Role
10%+ Owner
Signature
/s/ Nathan D. Hukill, authorized signatory for CR Group LP, CRG Partners III LP, CRG Partners III Parallel Fund (A) LP, CRG Partners III Parallel Fund B LP, CRG Partners III (Cayman) Unlev AIV I LP, CRG Partners III (Cayman) Lev AIV I LP
Issuer symbol
TTOO
Transactions as of
14 Feb 2024
Net transactions value
$0
Form type
4
Filing time
16 Feb 2024, 17:17:26 UTC
Previous filing
29 Sep 2023
Next filing
16 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTOO Common Stock Conversion of derivative security +335,947 335,947 14 Feb 2024 By CRG Partners III (Cayman) Lev AIV I L.P. F1, F2
transaction TTOO Common Stock Conversion of derivative security +488,273 488,273 14 Feb 2024 By: CRG Partners III Parallel Fund B LP F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TTOO Series B Preferred Stock Conversion of derivative security $0 -33,595 -100% $0.000000* 0 14 Feb 2024 Common Stock 335,947 By: CRG Partners III (Cayman) Lev AIV I L.P. F1, F2, F3
transaction TTOO Series B Preferred Stock Conversion of derivative security $0 -48,827 -82% $0.000000 10,875 14 Feb 2024 Common Stock 488,273 By: CRG Partners III Parallel Fund B LP F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration.
F2 CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
F3 The preferred stock has no expiration date.